1. What Is GHK-Cu
GHK-Cu (glycyl-L-histidyl-L-lysine:copper(II)) is a naturally occurring tripeptide — a chain of just three amino acids (glycine, histidine, and lysine) — that binds a single copper(II) ion. It was first isolated from human blood plasma by biochemist Loren Pickart in 1973, when he observed that a factor in young plasma could cause old liver tissue to behave like young tissue in cell culture.
GHK-Cu circulates in human blood, saliva, and urine. Plasma levels are approximately 200 ng/mL at age 20 and decline to roughly 80 ng/mL by age 60 — a reduction of about 60%. This age-related decline correlates with reduced regenerative capacity, though correlation is not causation.
The peptide is notable for its size. At approximately 340 Da for the free peptide (403.9 Da with the bound copper ion), GHK-Cu is one of the smallest biologically active peptides known. Its copper-binding property is not incidental — it is central to the peptide's biological activity.
2. Mechanism of Action
GHK-Cu's mechanisms have been studied for over 50 years. The evidence points to several pathways:
Copper Transport and Modulation
GHK-Cu is proposed to play a role in regulating copper uptake into cells. Copper is an essential cofactor for numerous enzymes involved in connective tissue formation, antioxidant defense, and energy metabolism. The peptide may facilitate copper delivery to cells at physiologically appropriate levels.
Collagen and Extracellular Matrix Stimulation
At picomolar to nanomolar concentrations, GHK-Cu has been shown to stimulate collagen synthesis in skin fibroblasts and increase accumulation of glycosaminoglycans and other extracellular matrix components. The GHK sequence is found within collagen itself and within the protein SPARC, which is abundant in tissues undergoing remodeling.
Angiogenesis
Like BPC-157, GHK-Cu has been observed to promote new blood vessel formation in wound healing studies. This is relevant to tissue repair but carries the same theoretical concern regarding existing tumors (see Limitations).
Gene Expression Modulation
Research using the Broad Institute's Connectivity Map has found that GHK-Cu is associated with the modulation of over 4,000 human genes. However, connectivity mapping identifies statistical associations between compounds and gene expression patterns — it does not establish that GHK-Cu causes specific clinical outcomes in humans.
3. Research Evidence
GHK-Cu has a longer research history than most peptides in this space, dating back to 1973. Key areas of published research include:
4. What the Research Does Not Show
- The strongest human evidence is topical, not injectable. Controlled human studies demonstrating benefits have used topical GHK-Cu formulations applied to skin. As of September 2026, there are no published randomized controlled trials of injectable GHK-Cu in humans.
- Gene expression data is associative, not causal. The finding that GHK-Cu modulates over 4,000 genes comes from connectivity mapping — a bioinformatics tool that identifies statistical patterns. This does not mean GHK-Cu produces 4,000 distinct clinical effects in a living human.
- Angiogenesis promotion is a double-edged mechanism. The same blood vessel formation that aids wound healing is a theoretical concern in the context of existing tumors. This has not been adequately studied in humans.
- Copper toxicity is a real consideration. Copper is essential in trace amounts but toxic in excess. The safety profile of supplemental GHK-Cu beyond topical application — particularly at doses exceeding physiological levels — is not well characterized in human studies.
- GHK-Cu is not approved by the FDA, Health Canada, or the EMA for any medical use as an injectable compound. Topical formulations are sold as cosmetics, not as drugs.
5. Purity and Lab Testing
GHK-Cu has several characteristics that are relevant to lab testing and quality evaluation:
HPLC Purity
Research-grade GHK-Cu from reputable suppliers typically tests at 98% or above via HPLC. Because GHK-Cu is a tripeptide (only 3 amino acids), it is relatively straightforward to synthesize at high purity compared to longer peptides.
Mass Spectrometry
The expected molecular weight is approximately 340 Da for the free GHK tripeptide and approximately 403.9 Da for the copper complex (GHK-Cu). Lab reports may show either value depending on whether the measurement was performed on the complexed or uncomplexed form.
Visual Identification
GHK-Cu in lyophilized form is a distinctive blue powder — the color comes from the bound copper(II) ion. A white or off-white powder marketed as GHK-Cu may indicate the absence of copper complexation, though visual inspection alone is not a reliable quality test.
Stability
GHK-Cu should be formulated at pH 5.5–7.0. Highly acidic conditions (pH 3–4) protonate the histidine residue that binds copper, potentially releasing free copper and reducing the peptide's activity. After reconstitution, store at 2–8°C and protect from light.
6. What to Look For in a GHK-Cu COA
When evaluating a COA for a GHK-Cu product, confirm the following:
HPLC purity of 98% or higher from a named, independent third-party lab
Mass spectrometry confirming molecular weight near 340 Da (free peptide) or 403.9 Da (copper complex)
Confirmation that the product is the copper-complexed form (GHK-Cu), not the free GHK tripeptide without copper
A batch or lot number that matches the product you received
A lab reference number you can verify directly with the testing lab
Appearance noted as blue powder — consistent with copper complexation
For a full walkthrough of evaluating a COA, see our guide to reading a peptide COA.
Summary
GHK-Cu is a naturally occurring copper-binding tripeptide with over 50 years of published research. The strongest human evidence supports topical applications for skin aging and wound healing. Injectable human trial data is absent. When evaluating GHK-Cu products, look for HPLC purity above 98%, mass spec confirmation at approximately 340 Da (free) or 403.9 Da (complexed), blue lyophilized powder, and proper pH formulation (5.5–7.0).